Bevacizumab-Based Therapies in the First-Line Treatment of Metastatic Colorectal Cancer

被引：60
|
作者：
Strickler, John H. [1 ]
Hurwitz, Herbert I. [1 ]
机构：
[1] Duke Univ, Med Ctr, Div Hematol & Oncol, Durham, NC 27710 USA
来源：
ONCOLOGIST | 2012年 / 17卷 / 04期
关键词：
Bevacizumab; Colorectal cancer; Drug toxicity; Combination drug therapy; Vascular endothelial growth factor; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; ARTERIAL THROMBOEMBOLIC EVENTS; OXALIPLATIN-BASED CHEMOTHERAPY; 2 DIFFERENT SCHEDULES; ANTI-VEGF; PLUS BEVACIZUMAB; ORAL FLUOROPYRIMIDINES; ANGIOGENESIS INHIBITOR; VENOUS THROMBOEMBOLISM;
D O I：
10.1634/theoncologist.2012-0003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Since its approval for the first-line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab-based treatment regimens, its use in various patient populations, and the identification of associated adverse events. This review discusses the results of several phase II and phase III clinical trials, as well as large observational studies, to address the use of bevacizumab in the treatment of patients with mCRC in the first-line setting. The Oncologist 2012;17:513-524
引用
收藏
页码：513 / 524
页数：12
相关论文
共 50 条
  • [1] Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer
    Guiu, Boris
    Petit, Jean Michel
    Bonnetain, Franck
    Ladoire, Sylvain
    Guiu, Severine
    Cercueil, Jean-Pierre
    Krause, Denis
    Hillon, Patrick
    Borg, Christophe
    Chauffert, Bruno
    Ghiringhelli, Francois
    [J]. GUT, 2010, 59 (03) : 341 - 347
  • [2] Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy
    Demircan, Nazim Can
    Dane, Faysal
    Ozturk, Mehmet Akif
    Babacan, Nalan Akgul
    Besiroglu, Mehmet
    Kaya, Serap
    Ercelep, Ozlem
    Tanrikulu, Eda
    Halil, Suleyman
    Koca, Sinan
    Alan, Ozkan
    Hasano, Rahip
    Yumuk, Perran Fulden
    [J]. JOURNAL OF BUON, 2019, 24 (04): : 1494 - 1500
  • [3] Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer
    Ito, Mamoru
    Kusaba, Hitoshi
    Mukaide, Satomi
    Kishimoto, Junji
    Shimokawa, Hozumi
    Tamura, Shingo
    Makiyama, Akitaka
    Hirano, Gen
    Oda, Hisanobu
    Shirakawa, Tsuyoshi
    Komoda, Masato
    Uchino, Keita
    Tanaka, Risa
    Mitsugi, Kenji
    Esaki, Taito
    Arita, Shuji
    Ariyama, Hiroshi
    Akashi, Koichi
    Baba, Eishi
    [J]. ANTI-CANCER DRUGS, 2017, 28 (10) : 1166 - 1173
  • [4] BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY FOR THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER
    Ubago, R.
    Castillo, M. A.
    Flores, S.
    Beltran, C.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A435 - A435
  • [5] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    Scartozzi, M.
    Giampieri, R.
    Maccaroni, E.
    Del Prete, M.
    Faloppi, L.
    Bianconi, M.
    Galizia, E.
    Loretelli, C.
    Belvederesi, L.
    Bittoni, A.
    Cascinu, S.
    [J]. BRITISH JOURNAL OF CANCER, 2012, 106 (05) : 799 - 804
  • [6] Progression-Free Survival in Bevacizumab-Based First-Line Treatment for Patients With Metastatic Colorectal Cancer: Is It a Really Good End Point?
    Montagnani, Francesco
    Migali, Cristina
    Fiorentini, Giammaria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : E132 - E133
  • [7] Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients
    M Scartozzi
    R Giampieri
    E Maccaroni
    M Del Prete
    L Faloppi
    M Bianconi
    E Galizia
    C Loretelli
    L Belvederesi
    A Bittoni
    S Cascinu
    [J]. British Journal of Cancer, 2012, 106 : 799 - 804
  • [8] KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy
    Cunha Pereira, T.
    Salgueiro, F.
    Monteiro, A.
    Felix Soares, R.
    Macedo, F.
    Jacinto, P.
    Paulo, J.
    Bonito, N.
    Marques, M.
    Ribeiro, J.
    Sousa, G.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S163 - S164
  • [9] Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
    Manzoni, M.
    Rovati, B.
    Ronzoni, M.
    Loupakis, F.
    Mariucci, S.
    Ricci, V.
    Gattoni, E.
    Salvatore, L.
    Tinelli, C.
    Villa, E.
    Danova, M.
    [J]. ONCOLOGY, 2010, 79 (3-4) : 187 - 196
  • [10] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    M J Safont
    A Salud
    F Losa
    C García-Girón
    C Bosch
    P Escudero
    R López
    C Madroñal
    M Bolaños
    M Gil
    A Llombart
    J Castro-Carpeño
    M González-Barón
    [J]. British Journal of Cancer, 2010, 102 : 1468 - 1473
12345